Product information and disease descriptionProduct descriptionProduct informationPharmacology
Mechanism of action
8 evidence topics · 9 sources
Allosteric insulin receptor antibody acting in liver, fat, and muscle
Selective and reversible reduction of insulin binding and signaling
“The activity of insulin on target tissues is mediated by insulin receptor signaling, which causes increased glucose uptake into tissues, glycogen synthesis, suppression of gluconeogenesis, and suppression of free fatty acids and ketones ( 9 , 10 ).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Ersodetug, a fully human insulin receptor–modulating antibody, engages an allosteric site on the insulin receptor to selectively and reversibly reduce insulin binding and signaling in a dose-dependent manner, leading to reduced insulin signaling ( 11 , 12 ).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Modulation without blocking insulin binding
Action on insulin and IGF-2 in both tumor types
Negative allosteric modulation: first-in-human publication
Reduced insulin affinity and signaling efficacy: discovery studies of XMetD
“Addition of insulin reduced the affinity of XMetD to the INSR by 3-fold, and XMetD reduced the affinity of the INSR for insulin 3-fold.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In addition to inhibiting INSR binding, XMetD also inhibited insulin-induced INSR signaling by 20- to 100-fold.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“These data indicated that XMetD was an allosteric antagonist of the INSR because, in addition to inhibiting the INSR via modulation of binding affinity, it also inhibited the INSR via modulation of signaling efficacy.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote